CRBP vs. LTRN, LPTX, ORGS, CEMI, TNXP, ZLAB, CPRX, GLPG, NAMS, and KROS
Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Lantern Pharma (LTRN), Leap Therapeutics (LPTX), Orgenesis (ORGS), Chembio Diagnostics (CEMI), Tonix Pharmaceuticals (TNXP), Zai Lab (ZLAB), Catalyst Pharmaceuticals (CPRX), Galapagos (GLPG), NewAmsterdam Pharma (NAMS), and Keros Therapeutics (KROS). These companies are all part of the "pharmaceutical preparations" industry.
Lantern Pharma (NASDAQ:LTRN) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, community ranking, media sentiment, valuation and risk.
Lantern Pharma has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500.
Corbus Pharmaceuticals received 420 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 75.00% of users gave Lantern Pharma an outperform vote while only 66.36% of users gave Corbus Pharmaceuticals an outperform vote.
Corbus Pharmaceuticals has a consensus price target of $67.67, indicating a potential upside of 53.33%. Given Lantern Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Lantern Pharma.
Lantern Pharma has higher earnings, but lower revenue than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.
Corbus Pharmaceuticals' return on equity of -41.17% beat Lantern Pharma's return on equity.
28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 6.9% of Lantern Pharma shares are held by company insiders. Comparatively, 4.0% of Corbus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Corbus Pharmaceuticals had 9 more articles in the media than Lantern Pharma. MarketBeat recorded 9 mentions for Corbus Pharmaceuticals and 0 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.36 beat Corbus Pharmaceuticals' score of 0.00 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media.
Summary
Corbus Pharmaceuticals beats Lantern Pharma on 9 of the 16 factors compared between the two stocks.
Get Corbus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corbus Pharmaceuticals Competitors List
Related Companies and Tools
